Related Experiment Video
Updated: Oct 7, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
Plasminogen activators: pharmacology and therapy
1Department of Radiology, Wishard Memorial Hospital, Indiana University School of Medicine, Indianapolis 46202.
Abstract:
Biochemical advances are providing new insights into coagulation and fibrinolysis. Integrating this biochemical knowledge into plasminogen activator therapy improves understanding of currently available enzymes. Basic components of the fibrinolytic system are discussed and the chemical structures, pharmacokinetics, dosages, and modes of delivery of current and future plasminogen activators are reviewed.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Venous Thrombosis III: Interprofessional Care

